Liver lipid metabolism disruption in cancer cachexia is aggravated by cla supplementation -induced inflammation
| العنوان: | Liver lipid metabolism disruption in cancer cachexia is aggravated by cla supplementation -induced inflammation |
|---|---|
| المؤلفون: | Alex Shimura Yamashita, Robson Eder, Daniela Caetano Gonçalves, Alessandro Laviano, Fábio Santos Lira, Luiz Carlos Carnevali Junior, Marilia Seelaender |
| المساهمون: | Universidade de São Paulo (USP), Universidade Federal de São Paulo (UNIFESP), Universidade Estadual Paulista (Unesp), Sapienza Univ Rome |
| المصدر: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Web of Science Repositório Institucional da UNESP Universidade Estadual Paulista (UNESP) instacron:UNESP |
| بيانات النشر: | Elsevier BV, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, medicine.medical_specialty, Cachexia, Apolipoprotein B, Adipose tissue, 030209 endocrinology & metabolism, Critical Care and Intensive Care Medicine, CAQUEXIA, Microsomal triglyceride transfer protein, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Neoplasms, Internal medicine, medicine, Animals, Linoleic Acids, Conjugated, Carnitine, Rats, Wistar, Inflammation, 030109 nutrition & dietetics, Nutrition and Dietetics, biology, Cholesterol, business.industry, Lipid metabolism, CLA, Lipid Metabolism, medicine.disease, Lipids, Rats, Endocrinology, Adipose Tissue, Liver, chemistry, Dietary Supplements, biology.protein, lipids (amino acids, peptides, and proteins), Carnitine palmitoyltransferase I, business, medicine.drug |
| الوصف: | Made available in DSpace on 2020-12-10T19:39:22Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-10-01 Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Background & aims: The liver is the main organ regulating metabolism. In spite of that, few studies examine liver metabolism in cachexia, a wasting syndrome associated with increased morbidity and mortality in cancer. Cachexia induces major metabolic disruption, inflammation and fat and lean mass loss. We have previously shown impairment of hepatic lipid metabolism in cancer cachexia that contributes to the aggravation of the symptoms. The present study addresses the effects of Conjugated Linoleic Acid supplementation upon liver lipid metabolism in cachectic rats. Methods: Male Wistar rats were randomly assigned to control groups (C) receiving 0.9 NaCl (Placebo -CP); or to groups supplemented with sunflower oil (CSF), supplemented with CLA (CCLA), or still, to tumour bearing animals (T) receiving NaCl (TP), sunflower oil (TSF), or CLA (TCLA). Supplementation (0.5 ml) by gavage was carried out for 14 days. Body weight, dietary intake, glucose, cholesterol and triacylglycerol plasma content, liver glycogen and triacylglycerol content and mRNA expression of liver carnitine palmitoyltransferase I and II (CPT I and II), as well as microsomal triglyceride transfer protein (MTP), liver fatty acid-binding protein (L-FABP), peroxisome proliferator-activated receptor-alpha (PPAR-alpha), and apolipoprotein B (apoB), were assessed. Results: Liver CPT II activity was reduced in all groups, when compared with CP. Hepatic mRNA expression of MTP, apoB and FABP was reduced in TCLA, when compared with all groups. TCLA also presented increased hepatic and plasma triacylglycerol content, when compared with all T groups. Adipose tissue-derived inflammatory factors were assessed. No differences among the groups were observed in regard to Retro Peritoneal Adipose Tissue cytokine (IL-1 beta, IL-6, and TNF-alpha) protein content and expression, with the exception of IL-10 in tumour-bearing animals. In the Epididymal Adipose Tissue, the inflammatory cytokines were augmented in TCLA, compared with all other groups. Conclusion: CLA supplementation fails to promote the re-establishment of hepatic lipid metabolism in tumour-bearing animals, and therefore is not recommended in cancer-related cachexia. (C) 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. Univ Sao Paulo, Canc Metab Res Grp, Inst Biomed Sci, Sao Paulo, Brazil Univ Sao Paulo, Fac Med, Sao Paulo, Brazil Univ Fed Sao Paulo UNIFESP, Biosci Dept, Campus Baixada Santista, Santos, Brazil Univ Estadual Paulista, Exercise & Immunometab Res Grp, Dept Phys Educ, Presidente Prudente, Brazil Sapienza Univ Rome, Dept Clin Med, Rome, Italy Univ Estadual Paulista, Exercise & Immunometab Res Grp, Dept Phys Educ, Presidente Prudente, Brazil FAPESP: 2012/50079-0 |
| تدمد: | 0261-5614 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efeda3b74ce03e9b5a06ef8c5022528dTest https://doi.org/10.1016/j.clnu.2018.09.023Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....efeda3b74ce03e9b5a06ef8c5022528d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 02615614 |
|---|